Cingulate Inc is a biopharmaceutical company focused on developing innovative treatments for patients with attention-related disorders, particularly attention deficit hyperactivity disorder (ADHD). The company's expertise lies in creating unique formulations that aim to improve medication adherence and enhance therapeutic outcomes for individuals affected by these conditions. Through advanced drug delivery systems and proprietary technologies, Cingulate is committed to addressing unmet medical needs and providing healthcare professionals with effective therapeutic options tailored to the complexities of ADHD. Read More
Cingulate Inc. (NASDAQ: CING) shares are soaring Friday. the stock is trading with a session volume of 3.297 million shares, approaching its 100-day average volume of 3.654 million shares.
Cingulate Inc. (NASDAQ: CING) shares are on an upward trajectory Friday. It follows the announcement that Cingulate has been granted European Patent No. 3261625 for its flagship asset, CTx-1301, which is designed to treat Attention Deficit Hyperactivity Disorder (ADHD).
